March 5, 2024

Engineered T Cells Market Size to Garner USD 348.9 Billion by 2032

The global Engineered T cells market size was estimated to be around US$ 20.21 billion in 2022. It is projected to reach US$ 348.9 billion by 2032, indicating a CAGR of 32.96% from 2023 to 2032.

Engineered T Cells Market Size 2023 To 2032

Key Takeaways

  • North America is expected to dominate in the market throughout the forecast period.
  • By Type, the chimeric antigen receptor (CAR) modified T cells segment led the market with the largest market share of 78% in 2022.
  • By End-user, the hospitals segment contributed more than 58% of revenue share in 2022.
  • By Application, the lung cancer segment is expected to be dominant in the market during the predicted period.

The market research report on the Engineered T cells market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of Engineered T cells products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.

Get a Sample:  https://www.precedenceresearch.com/sample/3224

Report Scope of the Engineered T Cells Market:

Report Coverage Details
Market Size in 2023 USD 26.87 Billion
Market Size by 2032 USD 348.9 Billion
Growth Rate from 2023 to 2032 CAGR of 32.96%
Largest Market North America
Base Year 2022
Forecast Period 2023 To 2032
Segments Covered By Type, By Application, and By End-user
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Read More: Electronic Components Market Size to Garner USD 368.4 Billion by 2032

The report presents the volume and value-based market size for the base year 2022 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.

Focusing on the global Engineered T cells market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the Engineered T cells market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.

Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of Engineered T cells products across different countries and applications.

Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2023 to 2032. It also includes accurate figures for production capacity and production by region during the same period.

The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.

This in-depth research report offers valuable insights into the Engineered T cells market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.

The competitive landscape section of the report provides detailed information on Engineered T cells market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the Engineered T cells market.

Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report

Reasons to Purchase this Report:

  • Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
  • In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
  • Market size in USD million and volume in million units provided for each segment and sub-segment.
  • Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
  • Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.

Key Market Players:

  • Amgen Inc
  • Bellicum Pharmaceuticals Inc.
  • Bristol-Myers Squibb
  • Precision Biosciences Inc.
  • Eli Lilly And Company
  • Gilead Sciences, Inc.
  • Novartis Ag
  • AthenexInc
  • Oxford BiomedicaPlc
  • Pfizer Inc.

Segments Covered in the Report:

By Type

  • Chimeric Antigen Receptor (CAR) Modified T Cells
  • T Cells Receptor (TCR) Modified T Cells
  • Tumor Infiltrating Lymphocytes

By Application

  • Lung Cancer
  • Colorectal Cancer
  • Melanoma
  • Breast Cancer
  • Leukemia

By End-user

  • Hospitals
  • Cancer Research Centers
  • Clinics

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Engineered T Cells Market 

5.1. COVID-19 Landscape: Engineered T Cells Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Engineered T Cells Market, By Type

8.1. Engineered T Cells Market, by Type, 2023-2032

8.1.1 Chimeric Antigen Receptor (CAR) Modified T Cells

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. T Cells Receptor (TCR) Modified T Cells

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Tumor Infiltrating Lymphocytes

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Engineered T Cells Market, By Application

9.1. Engineered T Cells Market, by Application, 2023-2032

9.1.1. Lung Cancer

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Colorectal Cancer

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Melanoma

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Breast Cancer

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Leukemia

9.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Engineered T Cells Market, By End-user 

10.1. Engineered T Cells Market, by End-user, 2023-2032

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Cancer Research Centers

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Clinics

10.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Engineered T Cells Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type (2020-2032)

11.1.2. Market Revenue and Forecast, by Application (2020-2032)

11.1.3. Market Revenue and Forecast, by End-user (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.1.4.3. Market Revenue and Forecast, by End-user (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.1.5.3. Market Revenue and Forecast, by End-user (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type (2020-2032)

11.2.2. Market Revenue and Forecast, by Application (2020-2032)

11.2.3. Market Revenue and Forecast, by End-user (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.2.4.3. Market Revenue and Forecast, by End-user (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.2.5.3. Market Revenue and Forecast, by End-user (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Application (2020-2032)

11.2.6.3. Market Revenue and Forecast, by End-user (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Application (2020-2032)

11.2.7.3. Market Revenue and Forecast, by End-user (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type (2020-2032)

11.3.2. Market Revenue and Forecast, by Application (2020-2032)

11.3.3. Market Revenue and Forecast, by End-user (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.3.4.3. Market Revenue and Forecast, by End-user (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.3.5.3. Market Revenue and Forecast, by End-user (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Application (2020-2032)

11.3.6.3. Market Revenue and Forecast, by End-user (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Application (2020-2032)

11.3.7.3. Market Revenue and Forecast, by End-user (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.4.3. Market Revenue and Forecast, by End-user (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.4.4.3. Market Revenue and Forecast, by End-user (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.4.5.3. Market Revenue and Forecast, by End-user (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Application (2020-2032)

11.4.6.3. Market Revenue and Forecast, by End-user (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Application (2020-2032)

11.4.7.3. Market Revenue and Forecast, by End-user (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.5.3. Market Revenue and Forecast, by End-user (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Application (2020-2032)

11.5.4.3. Market Revenue and Forecast, by End-user (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Application (2020-2032)

11.5.5.3. Market Revenue and Forecast, by End-user (2020-2032)

Chapter 12. Company Profiles

12.1. Amgen Inc

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Bellicum Pharmaceuticals Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Bristol-Myers Squibb

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Precision Biosciences Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Eli Lilly And Company

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Gilead Sciences, Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Novartis Ag

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. AthenexInc

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Oxford BiomedicaPlc

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Pfizer Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/

Prathamesh

I have completed my education in Bachelors in Computer Application. A focused learner having a keen interest in the field of digital marketing, SEO, SMM, and Google Analytics enthusiastic to learn new things along with building leadership skills.

View all posts by Prathamesh →

Leave a Reply

Your email address will not be published. Required fields are marked *